1. Introduction {#sec0005}
===============

Localised prostate cancer (PCa) treatment currently involves surgery or radiotherapy applied to the whole prostate regardless of the location or volume of individual PCa lesions. Although there is a survival benefit from this approach in men with intermediate- and high-risk disease, radical whole-gland therapies are associated with a significant risk of rectal complications, incontinence, and impotence [@bib0005; @bib0010]. Tissue-preserving focal therapy, in which only areas of known cancer are targeted, may improve the therapeutic ratio [@bib0015; @bib0020; @bib0025; @bib0030; @bib0035]. A number of early-phase studies have shown that preservation of genitourinary function can be high following focal therapy, although cancer control in the medium and long term is yet to be fully evaluated [@bib0040; @bib0045; @bib0050; @bib0055].

One of the key challenges with focal therapy is to accurately identify the population of men who are potentially suitable for tissue preservation. Some practitioners have argued that focal therapy is an alternative in men suitable for active surveillance [@bib0015; @bib0025; @bib0060], while others have argued that focal therapy should be investigated as a potential alternative to radical therapy in those men likely to benefit from treatment [@bib0020; @bib0030; @bib0060; @bib0065]. This argument incorporates the concept of ablating the index cancer lesion, which usually harbours the highest grade and largest cancer volume [@bib0070]. A number of ethics committee--approved trials are currently recruiting men with intermediate- and high-risk disease and treating them in an index lesion--ablative manner [@bib0075; @bib0080; @bib0085].

Therefore, the population of men who are potentially eligible for focal therapy is likely to vary with respect to risk group and is dependent on the focal therapy strategy. Studies using whole-mount prostatectomy specimens to estimate this population might incorporate selection bias, since men would have chosen surgery rather than any number of other treatment modalities. We sought to evaluate the proportion of men suitable for focal therapy based on transperineal template prostate-mapping (TTPM) biopsies, as this test can be applied to all men prior to treatment.

2. Methods {#sec0010}
==========

This study received exemption from ethics committee approval from the University College London Hospitals Joint Research Office. Our institutional TTPM biopsy registry includes all cases having this procedure. The majority of these patients were tertiary referrals to our institution with previous transrectal ultrasound--guided biopsies. TTPM biopsies were conducted using a method previously described, with cores taken every 5 mm throughout the prostate using a template grid ([Fig. 1](#fig0005){ref-type="fig"}) [@bib0090]. Antibiotic prophylaxis was used with single-dose cefuroxime, gentamicin, and metronidazole at the time of induction. The complications were assessed on immediate postoperative findings and any hospital readmissions and were enquired of the patient at the 4--6-wk follow-up visit. The cancer risk group was determined using the US National Comprehensive Cancer Network (NCCN) guidelines. Locoregional radiologic staging was performed using prostate magnetic resonance imaging (MRI), and distant metastases were ruled out using a pelvic MRI and radioisotope bone scan in any man with a Gleason score ≥7 on any histology, prostate-specific antigen ≥10 ng/ml, or clinical/MRI T stage ≥T3a. The T stage was based on MRI characteristic only and not on histology [@bib0095].

Toxicity data were collected retrospectively through review of clinic notes and are reported for completeness, although they may be subject to recall bias. Criteria used to decide suitability for focal therapy were those used in prospective ethics committee--approved trials actively recruiting during the period of this study, with pathologic tumour features characterised according to a combination of cancer core length and Gleason grade [@bib0100] ([Fig. 2](#fig0010){ref-type="fig"}). We have reported the results of two of these studies [@bib0045; @bib0055]. A third trial treating the index lesion is currently closed for analysis [@bib0090]. Our current multicentre focal therapy trial incorporates all these focal therapy strategies and will aim to recruit 150 men [@bib0100].

In summary, suitability for focal therapy required the cancer to be (1) unifocal, (2) unilateral, (3) bilateral/bifocal with at least one neurovascular bundle avoided, or (4) bilateral/multifocal with one dominant index lesion and secondary lesions with Gleason ≤3 + 3 and cancer core involvement ≤3 mm. The avoidance of the neurovascular bundle was based on ensuring that the posterior left or right quadrant of prostate tissue was not ablated. We accept that the neurovascular bundle is not a discrete bundle but has a more complex diffuse anatomic distribution. We felt that the avoidance of a posterior quadrant at least would avoid most of the ipsilateral nerves in question.

Because of the nonparametric nature of the data, a chi-square test or Spearman rank order for correlation was used, depending on expected values in the two-by-two tables. Cancer risk groups, in addition, were dichotomised at the low/intermediate and intermediate/high thresholds to reflect two schools of thought about the placement of focal therapy. First, some practitioners believe that focal therapy is an alternative for only those men suitable for active surveillance. Second, others have argued that focal therapy is an alternative for men with clinically significant cancer as a strategy that might overcome the harms of treatment but retain the cancer control benefits. A binary logistic regression model was also used, since the predictor variables were a combination of continuous and categorical variables and not normally distributed. Each logistic regression model used nine predictor variables. All tests were two-tailed and performed within SPSS statistical software v.17.0 (2010; IBM Corp., Armonk, NY, USA), and significance was defined as a *p* value \<0.05.

3. Results {#sec0015}
==========

An unselected cohort of 377 men referred to our institution underwent TTPM biopsy between 2006 and 2010; of these men, 291 had no previous treatment and formed our cohort for analysis ([Fig. 3](#fig0015){ref-type="fig"}, [Tables 1 and 2](#tbl0005 tbl0010){ref-type="table"}). The side-effects of TTPM included perineal ecchymosis in 100% of the men (291 of 291); mild, self-resolving haematuria in most; haematuria requiring admission in 2% (6 of 291); urinary retention in 7% (20 of 291); urinary tract infection in 1% (3 of 291); scrotal skin cellulitis in 0.3% (1 of 291); and no sepsis. We did not routinely collate data on erectile dysfunction at baseline or follow-up, so the actual number with haematospermia is unknown.

Ninety-two percent of men with cancer (220 of 239 men) on TTPM biopsy were suitable for at least one form of focal therapy: hemiablation (22%, 53 of 239 men), unifocal ablation (31%, (73 of 239 men), bilateral/bifocal ablation (14%, 33 of 239 men), and index lesion ablation (26%, 61 of 239 men) ([Table 3](#tbl0015){ref-type="table"}). Based on univariate analysis, being in the NCCN high-risk group was a statistically significant predictive factor for men not suitable for focal therapy, although numbers were small ([Table 4](#tbl0020){ref-type="table"}). When dichotomising between low- and intermediate/high-risk groups, the proportion of men suitable for focal therapy decreased from 99% (84 of 85 men) to 91% (94 of 106 men), respectively (*p* = 0.005). When dichotomising between low/intermediate-risk compared with high-risk groups, 95% (166 of 175 men) compared with 75% (12 of 16 men) were suitable for focal therapy (*p* = 0.002).

On binary logistic regression modelling that incorporated transrectal biopsy parameters, we found no statistically significant predictive factor for focal therapy suitability. However, when TTPM biopsy variables were used instead, stage (specifically, radiologic T2c) was a significant negative predictor (*p* = 0.001) (odds ratio: 0.001 \[95% confidence interval, 0.000--0.048\]) ([Table 5](#tbl0025){ref-type="table"}).

4. Discussion {#sec0020}
=============

Approximately 90% of men presenting with low- and intermediate-risk disease in our cohort were suitable for at least one focal therapeutic strategy using TTPM biopsy as a means to localise individual PCa lesions.

Our study has a number of limitations. First, as a tertiary centre, we had men presenting to us who were interested in focal therapy. This situation might have led to selection bias, as men with larger cancer burdens on transrectal biopsy may not have sought further risk stratification or trials in focal therapy. This bias is difficult to quantify. Second, as there is no clear consensus as to which risk category for focal therapy should be investigated [@bib0015; @bib0020; @bib0025; @bib0030; @bib0075; @bib0080], our inclusion of intermediate- and high-risk groups may be controversial. We have tried to reflect this lack of consensus by describing all risk groups in an open manner. Third, although we found that clinical T stage was the only negative predictor for suitability of focal therapy, it must be noted that clinical T stage does not correlate very well with final pathologic stage or final oncology outcome after definitive treatment. Fourth, it is clearly important to remember that while defining the patient population is important and facilitates decision making in clinical practice and research, focal therapy has no long-term outcomes on disease control and is thus not yet considered standard care. Finally, there is no gold standard control with which to compare the results of TTPM biopsy; hence, the accuracy of TTPM biopsy in tumour localisation may be questioned. However, both simulation models [@bib0105] and a radical prostatectomy comparison study [@bib0110] reflect a high level of fidelity. At the same time, we acknowledge that lack of definitive final histology could have an unquantifiable bias in the current study.

A large study population, accurate data collection, and mapping of individual cores of the TTPM biopsies for every patient added strength to the study. The different focal therapy strategies are based on our prospective trials and are thus not just theoretical concepts. We have previously shown that of men with low- and intermediate-risk disease who have undergone radical prostatectomy, between 51% and 68% would have been suitable for a form of focal therapy including index lesion ablation [@bib0115; @bib0120]. Other researchers have identified that only one-fifth to one-third of men may be suitable [@bib0125]. These differences may be due to controversy surrounding the concept of the index lesion and whether it is safe to leave low-grade, low-volume lesions untreated. We have included this concept as a focal therapeutic strategy, since men are currently being treated in this manner within the context of ethics committee--approved trials [@bib0085; @bib0090; @bib0095]. Indeed, many focal therapy series in which transrectal biopsy is used to localise lesions are likely to be treating by an index lesion ablation de facto.

Our study has relevance on a number of levels. First, when patients wish to explore focal therapy and are recommended to have a general anaesthetic and multiple biopsies, which carry some additional toxicity, they are likely to want to know the odds that they might be found to have suitable disease for focal therapy. Second, physicians offering template biopsies with a view to focal therapy are better placed to advise and counsel while also being able to make a judgement on whether the additional resources are worthwhile for their particular health care setting. Third, with designs for randomised controlled trials of focal therapy compared with radical therapy being considered, there is a key issue about when to apply a template biopsy with respect to the timing of randomisation. If template biopsies are conducted prior to randomisation, men potentially go through a morbid, high-burden test that will have little clinical relevance if they are randomised to the control arm. If templates are conducted after randomisation and only in the focal arm, but a large proportion of men are then not suitable for focal therapy (therefore, they have radical therapy), this situation would be problematic from an intention-to-treat analysis. Our study has shown that template biopsies after randomisation would not necessarily lead to significant rates of whole-gland therapy in the focal therapy arm.

There are no widely accepted standards for disease localisation in focal therapy, since studies have shown that transrectal biopsy on its own is not sufficient [@bib0130]. However, TTPM biopsy is more invasive and requires considerable health care resources. Its major advantage is high sensitivity and negative predictive value for detecting and ruling out lesions with 0.5-ml volume [@bib0140]. Since our early focal therapy trials formed some of the first trials and followed a phased programme [@bib0135], we decided to use TTPM biopsy to ensure, with a high degree of confidence, that clinically significant disease was not left untreated. Since then, evidence on multiparametric MRI shows that this modality might have negative predictive values of 90--95% for ruling out clinically significant PCa (Gleason ≥3 + 4 and/or lesion ≥0.5 ml) using whole-mount prostatectomy [@bib0140; @bib0145] or TTPM [@bib0150] as a reference standard and thus might have a role in focal therapy disease localisation.

5. Conclusions {#sec0025}
==============

The success of tissue-preserving focal therapy is dependent on appropriate patient selection. This selection necessitates an accurate investigative tool that can exclude significant cancer outside the area intended to be ablated while precisely localising individual cancer lesions, which are to be selectively destroyed. When such a test, TTPM biopsy, was applied to men with low- and intermediate-risk PCa, most men were found to be suitable for a tissue preservation strategy. Whether such a tissue-preserving strategy gives long-term favourable oncologic outcomes is currently being evaluated by various ongoing focal therapy trials.
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![Template prostate-mapping biopsies. (a) Biopsies are taken every 5 mm through a template brachytherapy grid using a method described by Winston Barzell. Biopsies are still taken every 5 mm throughout the prostate, and two biopsies are taken from the same grid coordinate if the prostate is longer than the length of one core biopsy [@bib0095]. (b) Regional method used on template-mapping biopsy. Although 5-mm sampling is carried out, the biopsies are batched into 20 zones to limit pathology burdens. The colour coding of individual lesions/zones is based on Kirkham et al. [@bib0095]. In this case, index lesion ablation could be targeted to the left peripheral zone lesion and the low-volume, low-grade cancer in zone 20 left untreated. Reprinted from [@bib0090] with permission from Elsevier.](gr1){#fig0005}

![The morphologic characteristics of localised prostate cancers that were deemed suitable and not suitable for focal therapy: (a) unilateral disease, hemiablation; (b) unifocal disease, unifocal ablation; (c) bilateral bifocal disease, bifocal ablation; (d and e) index lesion with low-volume, low-grade lesion or lesions in contralateral areas, index lesion ablation; (f) bilateral high-volume or high-grade disease, not suitable for focal therapy.](gr2){#fig0010}

![Flowchart demonstrating patient population characteristics.\
TTPM = transperineal template prostate mapping; TRUS = transrectal ultrasound; HIFU = high-intensity focussed ultrasound.](gr3){#fig0015}

###### 

Baseline characteristics in 291 men undergoing transperineal template prostate-mapping biopsy

  Baseline characteristics                                                Value
  ----------------------------------------------------------------------- --------------------------
  Age, yr, median (IQR) (overall range)                                   61 (9) (40--81)
  Serum PSA, ng/ml, median (IQR) (overall range)                          6.8 (5.5) (2.1--24.8)
  Prostate volume, ml, median (IQR) (overall range)                       35.0 (18) (15--113)
  PSA density, ng/ml per cubic centimetre, median (IQR) (overall range)   0.17 (0.14) (0.02--0.99)
  Initial biopsy strategy, no. (%)                                        
   TRUS biopsy                                                            267 of 291 (92)
   TTPM biopsy                                                            24 of 291 (8)
  Gleason (if positive on TRUS-guided biopsy), no. (%)                    
   6                                                                      
    3 + 3                                                                 163 of 233 (70)
   7                                                                      56 of 233 (24)
    3 + 4                                                                 46 of 233 (20)
    4 + 3                                                                 10 of 233 (4)
   Missing                                                                17 of 233 (6)
  TRUS-guided biopsies                                                    
   Total cores, no., median (IQR) (overall range)                         10 (4) (3--18)
   Total positive cores, no., median (IQR) (overall range)                2 (2) (1--10)
   Positive cores, %, median (IQR) (overall range)                        6.0 (6.5) (1.2--24.0)
   MCL, mm, median (IQR) (overall range)                                  3 (4) (1--14)
   % MCL, median (IQR) (overall range)                                    25 (30) (1--100)
  TRUS biopsy laterality, no. (%)                                         
   Unilateral                                                             199 of 233 (85)
   Bilateral                                                              23 of 233 (10)
   Missing                                                                11 of 233 (5)
  Radiologic (MRI) stage, no. (%)                                         
   T1c                                                                    85 of 239 (36)
   T2a                                                                    105 of 239 (44)
   T2b                                                                    27 of 239 (11)
   T2c                                                                    5 of 239 (2)
   T3a                                                                    17 of 239 (7)
  Risk group (NCCN) after TRUS biopsy, no. (%)                            
   Low                                                                    102 of 233 (44)
   Intermediate                                                           98 of 233 (42)
   High                                                                   16 of 233 (7)
   Missing                                                                17 of 233 (7)

IQR = interquartile range; PSA = prostate-specific antigen; TRUS = transrectal ultrasound; TTPM = transperineal template prostate mapping; MCL = maximum cancer length; MRI = magnetic resonance imaging; NCCN = National Comprehensive Cancer Network.

Note: Of men with positive TRUS biopsy, 25 (12%) had a negative TTPM biopsy.

###### 

Details of transperineal template prostate-mapping biopsies in 291 men

  Characteristics                                                               Value
  ----------------------------------------------------------------------------- -----------------------
  Reason for undergoing TTPM biopsies, no. (%)                                  
   Positive TRUS biopsy                                                         233 of 291 (80)
    Risk stratification                                                         69 of 291 (24)
    Focal therapy                                                               164 of 291 (56)
   Negative TRUS biopsy, persistent risk                                        34 of 291 (12)
   Diagnostic (no previous TRUS biopsy)                                         24 of 291 (18)
  TTPM biopsies                                                                 
   Total cores, no., median (IQR) (overall range)                               29 (18) (10-- 0)
   Core density (biopsies per cubic centimetre), median (IQR) (overall range)   1.1 (1.2) (0.4--7.5)
   Total positive cores, no., median (IQR) (overall range)                      8 (5) (2--31)
   Positive cores, %, median (IQR) (overall range)                              5.2 (6.8) (0.6--74.0)
   MCL, mm, median (IQR) (overall range)                                        6 (5) (1--15)
   % MCL, median (IQR) (overall range)                                          50 (55) (3--100)
  Gleason (TTPM biopsies), no. (%)                                              
   No cancer                                                                    52 of 291 (18)
   3 + 3                                                                        96 of 291 (33)
   Score 7                                                                      127 of 291 (44)
    3 + 4                                                                       119 of 291 (41)
    4 + 3                                                                       8 of 291 (3)
   4 + 4                                                                        1 of 291 (0.3)
   Not gradable                                                                 15 of 291 (5)
  Risk group (NCCN) after TTPM, no. (%)                                         
   Low                                                                          70 of 239 (29)
   Intermediate                                                                 144 of 239 (60)
   High                                                                         20 of 239 (8)
   Missing                                                                      5 of 239 (2)
  TTPM laterality, no. (%)                                                      
   Unilateral                                                                   94 of 239 (39)
    Right                                                                       45 of 239 (19)
    Left                                                                        49 of 239 (21)
   Bilateral                                                                    145 of 239 (61)

TTPM = transperineal template prostate mapping; TRUS = transrectal ultrasound; IQR = interquartile range; MCL = maximum cancer length; NCCN = National Comprehensive Cancer Network.

Note: Of men with positive TRUS biopsy, 25 (12%) had a negative TTPM biopsy.

###### 

The proportion of men suitable for focal therapy following positive transperineal template prostate-mapping biopsy

  Focal strategy                                                           Value, no. (%)
  ------------------------------------------------------------------------ -----------------
  Suitable for focal therapy                                               220 of 239 (92)
  Not suitable for focal therapy                                           19 of 239 (8)
  Unilateral disease ([Fig. 2](#fig0010){ref-type="fig"}a and 2b)          
   Suitable for focal therapy                                              126 of 239 (53)
    Hemiablation ([Fig. 2](#fig0010){ref-type="fig"}a)                     53 of 239 (22)
    Unifocal ablation ([Fig. 2](#fig0010){ref-type="fig"}b)                73 of 239 (31)
   Not suitable for focal therapy                                          0 (0)
  Bilateral disease ([Fig. 2](#fig0010){ref-type="fig"}c-- 2f)             
   Suitable for focal therapy                                              94 of 239 (39)
    Bilateral focal ablation ([Fig. 2](#fig0010){ref-type="fig"}c)         33 of 239 (14)
    Index lesion ablation only ([Fig. 2](#fig0010){ref-type="fig"}d--2f)   61 of 239 (26)
   Not suitable for focal therapy                                          19 of 239 (8)

###### 

The relationship of suitability for focal therapy and risk groups following transperineal template prostate-mapping biopsies

  NCCN category based on TTPM biopsy   Unsuitable for focal therapy, no. (%)   Suitable for focal therapy, no. (%)   
  ------------------------------------ --------------------------------------- ------------------------------------- ----------------------------------------------------------------------------
   Low                                 3 of 70 (4)                             67 of 70 (96)                         Spearman rank order correlation (expected cell frequency \<5), *p* = 0.017
   Intermediate                        10 of 140 (7)                           130 of 140 (93)                       
  High                                 5 of 18 (28)                            13 of 18 (72)                         
   Low                                 3 of 70 (4)                             67 of 70 (96)                         Pearson chi-square, *p* = 0.179
   Intermediate and high               15 of 158 (10)                          143 of 158 (91)                       
  Low and intermediate                 13 of 210 (6)                           197 of 210 (94)                       Spearman rank order correlation (expected cell frequency \<5), *p* = 0.001
   High                                5 of 18 (28)                            13 of 18 (72)                         

TTPM = transperineal template prostate mapping; NCCN = National Comprehensive Cancer Network.

###### 

The role of transrectal biopsy and transperineal template prostate-mapping biopsy parameters in combination with other clinical baseline parameters to predict subsequent suitability for focal therapy (binary logistic regression)

  Variables                                                                        Odds ratio   *p* value
  -------------------------------------------------------------------------------- ------------ -----------
  Variables for binary logistic regression model based on TRUS biopsy parameters                
  Age                                                                              0.000        0.989
  PSA                                                                              0.000        0.996
  Total number of cores                                                            0.000        0.990
  Number of positive cores                                                         0.000        0.972
  Maximum cancer length                                                            \<0.001      0.989
  Gleason score (with respect to Gleason 6)                                                     
   Gleason 7                                                                       \<0.001      0.973
  Volume                                                                           1.779        0.995
  Stage (with respect to stage T1c)                                                             1.000
   Stage T2a                                                                       0.000        0.982
   Stage T2b                                                                       0.000        0.987
   Stage T2c                                                                       0.000        0.989
   Stage T3a                                                                       0.000        0.991
  NCCN risk (with respect to low risk)                                                          1.000
   Intermediate                                                                    0.000        0.979
   High                                                                            \<0.001      0.995
  Variables for binary logistic regression model based on TTPM parameters                       
  Age                                                                              1.023        0.665
  PSA                                                                              0.938        0.362
  Volume                                                                           0.997        0.908
  Stage (with respect to stage T1c)                                                             0.007
   Stage T2a                                                                       0.253        0.298
   Stage T2b                                                                       0.041        0.084
   Stage T2c                                                                       0.001        0.001
   Stage T3a                                                                       0.000        1.000
  NCCN risk (with respect to low risk)                                                          0.835
   Intermediate                                                                    2.306        0.548
   High                                                                            \<0.001      1.000
  Total number of cores                                                            1.019        0.475
  Number of positive cores                                                         0.937        0.254
  Maximum cancer length                                                            0.870        0.481
  TTPM Gleason score (with respect to Gleason 6)                                                0.943
   Gleason 7                                                                       1.472        0.733
   Gleason 8                                                                       0.000        1.000

TRUS = transrectal ultrasound; TTPM = transperineal template prostate mapping;

PSA = prostate-specific antigen; NCCN = National Comprehensive Cancer Network.
